Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been given an average recommendation of “Hold” by the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $13.75.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a research note on Tuesday.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $9.27 on Tuesday. Theravance Biopharma has a fifty-two week low of $7.44 and a fifty-two week high of $10.90. The firm has a market capitalization of $455.84 million, a P/E ratio of -9.18 and a beta of 0.21. The company’s 50 day moving average price is $9.34 and its two-hundred day moving average price is $8.92.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The business had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million. On average, analysts expect that Theravance Biopharma will post -1.09 earnings per share for the current year.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 309,565 shares of the company’s stock, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Aquatic Capital Management LLC bought a new stake in Theravance Biopharma during the 4th quarter worth approximately $25,000. Quantbot Technologies LP bought a new position in shares of Theravance Biopharma in the 3rd quarter worth $60,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Theravance Biopharma in the 4th quarter valued at $69,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Theravance Biopharma by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,696 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in Theravance Biopharma during the 4th quarter valued at $103,000. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.